STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE
개요
출원인
Northsea Therapeutics B.V.; BASF AS
발명자
David Alan FRASER; Tore SKJAERET; Detlef SCHUPPAN
IPC 분류
CPC 분류
The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.
원문 (중국어)
The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.